Teva Pharmaceutical Industries Ltd.’s attempts to add a “meaningful” additional market for one of its newer specialty brands, Austedo, have hit the buffers after two late-stage studies failed to show its benefit as a treatment for Tourette’s syndrome.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?